ArticleFuture healthcare journal2025
Rheumatology 2050: How our specialty is changing.
Article in Future healthcare journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Biosimilars: A Systematic Review of Machine Learning Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatology has undergone unprecedented transformation over the past quarter century, evolving from broad-spectrum immunosuppression to precision therapeutics targeting specific immune pathways. As the clinical, biological and economic landscape continues to evolve, understanding emerging trends is crucial for shaping the future of the specialty. In this narrative review, we will examine contemporary themes that will define rheumatology by 2050, spanning key areas of rheumatological practice, including precision medicine, genomic discoveries, disease prevention, cellular therapies and healthcare economics. Multiple transformative trends are currently reshaping rheumatology. Precision medicine is advancing beyond single-pathway targeting towards molecular stratification integrating serology, genomics and synovial pathotyping. Whole-exome sequencing has revealed new disease entities such as vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, while disease interception strategies show promise for preventing established autoimmunity, with trials demonstrating potential relative risk reduction in rheumatoid arthritis development using abatacept in at-risk individuals. Chimeric antigen receptor T-cell therapy has achieved complete clinical remission in severe systemic lupus erythematosus, while immune checkpoint inhibitor-induced rheumatic diseases present new diagnostic challenges. Environmental pressures, including air pollution and occupational exposures, are increasingly recognised as disease drivers. In the UK, national audit data show disparities in access to advanced therapies even within a universal healthcare system. Artificial intelligence integration promises enhanced diagnostics and monitoring, while economic pressures necessitate innovative funding models, with biosimilars demonstrating potential for expanding treatment access. By 2050, rheumatology will be characterised by molecularly stratified diseases, more affordable and accessible targeted therapies, curative cellular interventions and digital clinical ecosystems. Success will depend not only on technological advances but on ensuring equitable access, affordability, and preservation of patient-centred care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.